Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Revenue from Medicare comprised 24% and 25% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
$16M relationship
basisXGN fy2025 · closed 2025-12 $67M
FILING10-K0001274737-26-000009cik 0001274737
“We have been utilizing both United Parcel Service (UPS) and Federal Express Corporation (Federal Express) for reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens.”
FILING10-K0001274737-26-000009cik 0001274737
“We have been utilizing both United Parcel Service (UPS) and Federal Express Corporation (Federal Express) for reliable and secure point-to-point transport of patient specimens to our laboratory and enhanced tracking of these patient specimens.”
FILING10-K0001274737-26-000009cik 0001274737
“Our collaborative efforts with the Allegheny Health Network Research Institute (AHN) have resulted in further development of the T-Cell Biomarkers, for which we obtained an exclusive, worldwide license from AHN in May 2021 and launched commercially in January 2025 as part of the AVISE ® CTD test.”
FILING10-K0001274737-26-000009cik 0001274737
“In November 2023, we entered into an exclusive license agreement with JHU, under which we obtained an exclusive, worldwide license to JHU's patent rights in certain inventions (the JHU Patent Rights) related to methods of using urinary protein biomarkers as a means of risk stratifying lupus nephritis patients and predicting treatment response.”
FILING10-K0001274737-26-000009cik 0001274737
“During the year ended December 31, 2025, we sold 360,554 shares of common stock under the Amended Sales Agreement at an average per share price of $9.82, for gross proceeds of approximately $3.5 million and net proceeds of approximately $3.4 million after deducting $0.1 million in commissions paid to TD Cowen and other offering expenses payable by us.”
FILING10-K0001274737-26-000009cik 0001274737
“In August 2011, we entered into an amended and restated exclusive license agreement (the UPitt License Agreement) with the University of Pittsburgh (UPitt), through which we obtained an exclusive license to UPitt's patent rights in certain inventions (the UPitt Patent Rights) related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE ® testing products.”
FILING10-K0001274737-26-000009cik 0001274737
“Noridian, our MAC, has set the current pricing for this PLA code at $840.65 per test.”
FILING10-K0001274737-26-000009cik 0001274737
“We have a current certificate of accreditation under CLIA because we are accredited to perform testing by CAP.”
FILING10-K0001274737-26-000009cik 0001274737
“Loss on extinguishment of debt consists of the unamortized debt issuance costs and final payment fee due under the terms of our prior loan agreement, as amended, with Innovatus Life Sciences Lending Fund I, LP (the Amended Loan Agreement).”
FILING10-K0001274737-26-000009cik 0001274737
“A total of an additional $40.0 million is available at our option under the Perceptive Term Loan Facility as amended in March 2026 should we attain specified revenue levels and satisfy other conditions.”
FILING10-K0001274737-26-000009cik 0001274737
“AVISE ® Anti-CarP, is a biomarker-driven RA prognostic test, offered through a distribution agreement with Werfen USA, LLC to help identify RA patients with an increased risk for joint damage.”
FILING10-K0001274737-26-000009cik 0001274737
Watchlist prices, news filtered to it, and its next report on your desk.
Exagen Inc. has 9 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Exagen Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Exagen Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
Prev close 7.49 · gapped below the open, then crossed back over prior close. High/low 7.66 at 12:45 pm ET, 7.34 at 8:15 am ET.
XGN (Exagen Inc.) has 9 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: UPS +0.15%, in industrials & materials.